Corteva R&D Spending Growth & History (CTVA)
Corteva's r&d spending was $1.47B for fiscal 2025.
View full Corteva company overviewCorteva annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.47B | $72.0M | +5.14% |
| 2024 | 2024-12-31 | $1.40B | $65.0M | +4.86% |
| 2023 | 2023-12-31 | $1.34B | $121.0M | +9.95% |
| 2022 | 2022-12-31 | $1.22B | $29.0M | +2.44% |
| 2021 | 2021-12-31 | $1.19B | $45.0M | +3.94% |
| 2020 | 2020-12-31 | $1.14B | −$5.0M | −0.44% |
| 2019 | 2019-12-31 | $1.15B | −$208.0M | −15.35% |
| 2018 | 2018-12-31 | $1.35B | — | — |
Corteva quarterly r&d spending
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $388.0M | $13.0M | +3.47% |
| Q1 2026 | 2026-03-31 | $341.0M | $6.0M | +1.79% |
| Q4 2025 | 2025-12-31 | $413.0M | $48.0M | +13.15% |
| Q3 2025 | 2025-09-30 | $351.0M | $3.0M | +0.86% |
| Q2 2025 | 2025-06-30 | $375.0M | $18.0M | +5.04% |
| Q1 2025 | 2025-03-31 | $335.0M | $3.0M | +0.90% |
| Q4 2024 | 2024-12-31 | $365.0M | $8.0M | +2.24% |
| Q3 2024 | 2024-09-30 | $348.0M | $13.0M | +3.88% |
| Q2 2024 | 2024-06-30 | $357.0M | $28.0M | +8.51% |
| Q1 2024 | 2024-03-31 | $332.0M | $16.0M | +5.06% |
| Q4 2023 | 2023-12-31 | $357.0M | $17.0M | +5.00% |
| Q3 2023 | 2023-09-30 | $335.0M | $23.0M | +7.37% |
| Q2 2023 | 2023-06-30 | $329.0M | $33.0M | +11.15% |
| Q1 2023 | 2023-03-31 | $316.0M | $48.0M | +17.91% |
| Q4 2022 | 2022-12-31 | $340.0M | $24.0M | +7.59% |
| Q3 2022 | 2022-09-30 | $312.0M | $15.0M | +5.05% |
| Q2 2022 | 2022-06-30 | $296.0M | $3.0M | +1.02% |
| Q1 2022 | 2022-03-31 | $268.0M | −$13.0M | −4.63% |
| Q4 2021 | 2021-12-31 | $316.0M | $11.0M | +3.61% |
| Q3 2021 | 2021-09-30 | $297.0M | $13.0M | +4.58% |
| Q2 2021 | 2021-06-30 | $293.0M | $20.0M | +7.33% |
| Q1 2021 | 2021-03-31 | $281.0M | $1.0M | +0.36% |
| Q4 2020 | 2020-12-31 | $305.0M | $15.0M | +5.17% |
| Q3 2020 | 2020-09-30 | $284.0M | −$5.0M | −1.73% |
| Q2 2020 | 2020-06-30 | $273.0M | $4.0M | +1.49% |
| Q1 2020 | 2020-03-31 | $280.0M | −$19.0M | −6.35% |
| Q4 2019 | 2019-12-31 | $290.0M | −$4.0M | −1.36% |
| Q3 2019 | 2019-09-30 | $289.0M | −$36.0M | −11.08% |
| Q2 2019 | 2019-06-30 | $269.0M | −$85.0M | −24.01% |
| Q1 2019 | 2019-03-31 | $299.0M | −$83.0M | −21.73% |
| Q4 2018 | 2018-12-31 | $294.0M | — | — |
| Q3 2018 | 2018-09-30 | $325.0M | — | — |
| Q2 2018 | 2018-06-30 | $354.0M | — | — |
| Q1 2018 | 2018-03-31 | $382.0M | — | — |
Corteva r&d spending trends
Over the last five fiscal years, Corteva's r&d spending increased from $1.14B to $1.47B, a change of $332.0M. The latest reported quarter, Q2 2026, shows $388.0M.
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Corteva source filings ↗Community posts
Chemours, DuPont and Corteva agree to a $455 million PFAS settlement
Chemours ($CC), DuPont ($DD) and Corteva ($CTVA) reached an agreement to resolve PFAS-related claims brought by North Carolina and 11 local government entities. The settlement provides for $455 million in nominal payments over 15 years. Che ...